What you should know:
1. Cabozantinib can now be used in patients with hepatocellular carcinoma who were previously treated with sorafenib.
2. Cabozantinib is an orally-delivered drug which inhibits multiple receptors involved in cell function.
3. The FDA first approved the drug in 2012 as a treatment for thyroid cancer. The FDA approved the drug as a renal cancer treatment in 2016.
4. The FDA approved the drug for liver cancer patients based on a phase 3 study. In the study, patients treated with Cabozantinib saw their median survival rate increase 2.2 months.
More articles on gastroenterology:
What GI practices should look for in a PE partner — 5 Qs with Provident’s Abe M’Bodj
84 regional income, case mix benchmarks for ASCs to know
Why an Oklahoma-based ASC values autonomy — 3 insights
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.